After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Genome Editing Market Size Was Valued at USD 7.39 Billion in 2023, and is Projected to Reach USD 30.78 Billion by 2032, ...

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

Flashpoint Therapeutics, a clinical-stage therapeutics company pioneering structural nanomedicine, today announced significant expansion of its therapeutic pipeline through strategic acquisitions and ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

Salim Syed’s rating is based on a combination of encouraging developments surrounding Crispr Therapeutics AG. Firstly, the pricing of Casgevy in Saudi Arabia appears to be around $2 million per ...

The US FDA has cleared an investigational new drug (IND) application for HG202, by HuidaGene Therapeutics. This drug is the ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...